Tonghua Dongbao Pharmaceutical 미래 성장

Future 기준 확인 5/6

Tonghua Dongbao Pharmaceutical (는) 각각 연간 69.7% 및 24.4% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 71.4% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 15.4% 로 예상됩니다.

주요 정보

69.7%

수익 성장률

71.4%

EPS 성장률

Pharmaceuticals 수익 성장	18.3%
매출 성장률	24.4%
향후 자기자본 수익률	15.4%
애널리스트 커버리지	Good
마지막 업데이트	04 Nov 2024

최근 미래 성장 업데이트

업데이트 없음

Recent updates

수익 및 매출 성장 예측

XSSC:600867 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (CNY Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	3,907	1,320	N/A	1,317	5
12/31/2025	3,235	1,055	N/A	1,088	6
12/31/2024	2,148	132	N/A	601	3
9/30/2024	2,432	341	75	614	N/A
6/30/2024	2,449	453	227	667	N/A
3/31/2024	3,001	1,132	524	858	N/A
12/31/2023	3,075	1,168	513	862	N/A
9/30/2023	2,771	939	130	528	N/A
6/30/2023	2,757	884	213	611	N/A
3/31/2023	2,556	1,001	213	666	N/A
12/31/2022	2,778	1,582	370	863	N/A
9/30/2022	2,912	1,643	565	1,185	N/A
6/30/2022	2,993	1,820	405	1,160	N/A
3/31/2022	3,332	1,803	476	1,163	N/A
12/31/2021	3,268	1,308	580	1,180	N/A
9/30/2021	3,162	1,242	654	1,147	N/A
6/30/2021	3,079	1,060	849	1,188	N/A
3/31/2021	2,996	989	854	1,206	N/A
12/31/2020	2,892	930	713	1,192	N/A
9/30/2020	2,906	879	658	1,054	N/A
6/30/2020	2,817	820	794	1,174	N/A
3/31/2020	2,781	815	856	1,119	N/A
12/31/2019	2,777	811	859	1,152	N/A
9/30/2019	2,741	839	787	1,109	N/A
6/30/2019	2,664	834	477	1,001	N/A
3/31/2019	2,688	838	139	1,099	N/A
12/31/2018	2,693	839	104	877	N/A
9/30/2018	2,701	876	263	938	N/A
6/30/2018	2,827	963	N/A	954	N/A
3/31/2018	2,699	900	N/A	898	N/A
12/31/2017	2,545	837	N/A	961	N/A
9/30/2017	2,414	789	N/A	900	N/A
6/30/2017	2,332	736	N/A	818	N/A
3/31/2017	2,154	690	N/A	840	N/A
12/31/2016	2,040	641	N/A	726	N/A
9/30/2016	1,909	604	N/A	687	N/A
6/30/2016	1,779	546	N/A	577	N/A
3/31/2016	1,722	533	N/A	359	N/A
12/31/2015	1,669	493	N/A	295	N/A
9/30/2015	1,661	450	N/A	248	N/A
6/30/2015	1,576	393	N/A	105	N/A
3/31/2015	1,521	321	N/A	158	N/A
12/31/2014	1,451	280	N/A	206	N/A
9/30/2014	1,369	215	N/A	142	N/A
6/30/2014	1,308	216	N/A	285	N/A
3/31/2014	1,265	198	N/A	305	N/A
12/31/2013	1,204	184	N/A	221	N/A

애널리스트 미래 성장 예측

수입 대 저축률: 600867 의 연간 예상 수익 증가율( 69.7% )이 saving rate( 2.8% 보다 높습니다. ).

수익 vs 시장: 600867 의 연간 수익( 69.7% ) CN 시장( 26.2% 보다 빠르게 성장할 것으로 예상됩니다. 26.2% 연간).

고성장 수익: 600867 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.

수익 대 시장: 600867 의 수익(연간 24.4% ) CN 시장( 13.8% 보다 빠르게 성장할 것으로 예상됩니다. 13.8% 연간).

고성장 수익: 600867 의 수익(연간 24.4% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: 600867 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 15.4 %).

Tonghua Dongbao Pharmaceutical 미래 성장

Future 기준 확인 5/6

주요 정보

최근 미래 성장 업데이트

Recent updates

New minor risk - Earnings quality

Third quarter 2024 earnings released: EPS: CN¥0.059 (vs CN¥0.14 in 3Q 2023)

Tonghua Dongbao Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024

Investor sentiment improves as stock rises 16%

New minor risk - Profit margin trend

Now 21% overvalued

Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) announces an Equity Buyback for CNY 120 million worth of its shares.

Tonghua Dongbao Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024

First quarter 2024 earnings released: EPS: CN¥0.11 (vs CN¥0.13 in 1Q 2023)

Full year 2023 earnings released: EPS: CN¥0.59 (vs CN¥0.79 in FY 2022)

Tonghua Dongbao Pharmaceutical Co., Ltd., Annual General Meeting, Apr 19, 2024

Investor sentiment improves as stock rises 16%

Full year 2023 earnings released: EPS: CN¥0.59 (vs CN¥0.79 in FY 2022)

Tonghua Dongbao Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 08, 2024

Adocia Announces its Partner Tonghua Dongbao Releases Positive Results on the Three Clinical Studies Conducted on BioChaperone Combo THDB0207 Formulation Containing Insulin Glargine and Insulin Lispro from Tonghua Dongbao

Second quarter 2023 earnings released: EPS: CN¥0.11 (vs CN¥0.18 in 2Q 2022)

Tonghua Dongbao Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 22, 2023

Full year 2022 earnings released: EPS: CN¥0.79 (vs CN¥0.64 in FY 2021)

Investor sentiment improves as stock rises 16%

Full year 2022 earnings released: EPS: CN¥0.80 (vs CN¥0.64 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.19 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.18 (vs CN¥0.16 in 2Q 2021)

Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) commences an Equity Buyback for CNY 360 million worth of its shares, under the authorization approved on March 25, 2022.

First quarter 2022 earnings released: EPS: CN¥0.41 (vs CN¥0.17 in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: EPS: CN¥0.64 (vs CN¥0.46 in FY 2020)

Now 20% undervalued after recent price drop

Now 20% undervalued after recent price drop

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

An unknown buyer signed an agreement to acquire 5% stake in Xiamen Amoytop Biotech Co., Ltd. (SHSE:688278) from Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) for CNY 460 million.

Tonghua Dongbao Pharmaceutical Co., Ltd.(XSSC:600867) dropped from FTSE All-World Index (USD)

Third quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.10 in 3Q 2020)

Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) commences an Equity Buyback Plan for 24,000,000 shares, representing 1.18% for CNY 360 million, under the authorization approved on August 25, 2021.

Second quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.13 in 2Q 2020)

Full year 2020 earnings released: EPS CN¥0.46 (vs CN¥0.40 in FY 2019)

New 90-day low: CN¥11.82

Revenue misses expectations

Full year 2020 earnings released: EPS CN¥0.46

New 90-day low: CN¥12.87

New 90-day low: CN¥13.32

New 90-day high: CN¥14.91

Third quarter earnings released

Third-quarter earnings released: Revenue misses expectations

Earnings released

Tonghua Dongbao Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 20, 2020

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견